290 related articles for article (PubMed ID: 19815494)
1. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.
Van den Bosch F; Manger B; Goupille P; McHugh N; Rødevand E; Holck P; van Vollenhoven RF; Leirisalo-Repo M; Fitzgerald O; Kron M; Frank M; Kary S; Kupper H
Ann Rheum Dis; 2010 Feb; 69(2):394-9. PubMed ID: 19815494
[TBL] [Abstract][Full Text] [Related]
2. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
Gladman DD; ; Sampalis JS; Illouz O; Guérette B
J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
4. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
5. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
8. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Mease PJ; Ory P; Sharp JT; Ritchlin CT; Van den Bosch F; Wellborne F; Birbara C; Thomson GT; Perdok RJ; Medich J; Wong RL; Gladman DD
Ann Rheum Dis; 2009 May; 68(5):702-9. PubMed ID: 18684743
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J
Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964
[TBL] [Abstract][Full Text] [Related]
11. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
Mease PJ; Heckaman M; Kary S; Kupper H
J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
14. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adalimumab in Japanese patients with psoriatic arthritis and inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs): A prospective, observational study.
Morita A; Okuyama R; Katoh N; Tateishi C; Masuda K; Komori T; Ogawa E; Makino T; Nishida E; Nishimoto S; Muramoto K; Tsuruta D; Ihn H
Mod Rheumatol; 2020 Jan; 30(1):155-165. PubMed ID: 30836036
[No Abstract] [Full Text] [Related]
16. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
Zangrilli A; Bavetta M; Scaramella M; Bianchi L
G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
Atteno M; Peluso R; Costa L; Padula S; Iervolino S; Caso F; Sanduzzi A; Lubrano E; Del Puente A; Scarpa R
Clin Rheumatol; 2010 Apr; 29(4):399-403. PubMed ID: 20066450
[TBL] [Abstract][Full Text] [Related]
19. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.
van der Bijl AE; Breedveld FC; Antoni CE; Kalden JR; Kary S; Burmester GR; Beckmann C; Unnebrink K; Kupper H
Clin Rheumatol; 2008 Aug; 27(8):1021-8. PubMed ID: 18350329
[TBL] [Abstract][Full Text] [Related]
20. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
